ArticlePharmaceutics2025

Targeted Delivery of VEGF-siRNA to Glioblastoma Using Orientation-Controlled Anti-PD-L1 Antibody-Modified Lipid Nanoparticles.

Ayaka Matsuo-Tani et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.